Zymeworks
ZYME----
Zymeworks (ZYME)
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company’s platforms in...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Zymeworks Analyst Rating
View MoreForecast & Rating
Jul 13, 2026Price forecast
$39.3370.13%
Forecast & RatingStrong buy
12analysts
- Strong buy83.33%
- Buy16.67%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Global Report · 1 day ago, 04:18 AM
Beyond the Big Tech Platform Wars: The Fringe Economy from AI Cooling to Nuclear Fusion
- StockTitan · Jul 15 at 09:00 PM
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026 | ZYME Stock News
- Tip Ranks · Jul 8 at 09:02 PM
Major Theravance Biopharma Investor Makes Notable Stock Move
- Tip Ranks · Jun 30 at 04:55 AM
Zymeworks Earns Buy Rating as Non-Dilutive Theravance Deal and Long-Duration YUPELRI Cash Flows Drive Price Target Up to $37
- Pharmaceutical Business Review · Jun 30 at 03:00 AM
Zymeworks agrees to buy Theravance Biopharma for $929m
- TradingView · Jun 29 at 05:20 PM
Zymeworks Inc. Stock 12‑Month Price Target Raised to $38.75, Implies 60% Upside
